Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma
暂无分享,去创建一个
R. Or | M. Shapira | B. Avni | S. Grisariu
[1] S. Trestman,et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma , 2018, Bone Marrow Transplantation.
[2] G. Visani,et al. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning , 2016, Leukemia & lymphoma.
[3] G. Salles,et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT , 2016, Bone Marrow Transplantation.
[4] G. Visani,et al. Advancement in high dose therapy and autologous stem cell rescue in lymphoma. , 2015, World journal of stem cells.
[5] Robert Chen,et al. Brentuximab vedotin for the treatment of Hodgkin’s lymphoma , 2015, Expert review of hematology.
[6] N. Schmitz,et al. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study , 2015, British journal of haematology.
[7] S. Kvaløy,et al. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway , 2015, Haematologica.
[8] A. Lane,et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] P. Veys,et al. BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation , 2013, British journal of haematology.
[10] J. Armitage,et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. , 2013, Clinical lymphoma, myeloma & leukemia.
[11] I. Grotto,et al. Autologous transplant in multiple myeloma with an augmented conditioning protocol , 2013, Leukemia & lymphoma.
[12] S. Parmar,et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] A. LaCasce,et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant , 2012, Leukemia & lymphoma.
[14] G. Serio,et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma , 2012, Clinical and Experimental Medicine.
[15] Sang-We Kim,et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. , 2011, Leukemia research.
[16] C. Moskowitz,et al. Controversies in the treatment of lymphoma with autologous transplantation. , 2009, The oncologist.
[17] K. Goodman,et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Slavin,et al. The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation , 2007, Bone Marrow Transplantation.
[19] H. Lazarus,et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? , 2007, Bone Marrow Transplantation.
[20] N. Puig,et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation , 2006, Leukemia & lymphoma.
[21] W. Hiddemann,et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Ball,et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma , 2004, Bone Marrow Transplantation.
[23] J. Gribben,et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.